Nutriband Inc. reported its financial results for the first quarter ended April 30, 2025, highlighting a record revenue of $667,000, marking a 63% year-over-year increase. This notable rise in revenue is attributed to the company's continued expansion of its kinesiology tape production through its Pocono Pharma subsidiary. The strategy of penetration pricing has facilitated Nutriband's entry into major retail locations, such as Target, Walmart, Walgreens, and CVS, thereby enhancing shareholder value. In addition to financial performance, Nutriband Inc. is advancing the development of AVERSA Fentanyl, an innovative transdermal drug delivery solution. The company has solidified an exclusive product development partnership with Kindeva Drug Delivery. This collaboration involves shared development costs in exchange for milestone payments, aiming to achieve regulatory approval and commercialization of AVERSA Fentanyl, potentially the world's first abuse-deterrent opioid patch. The product could reach peak annual U.S. sales between $80 million and $200 million, according to the Health Advances Aversa Fentanyl market analysis report from 2022.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.